We aimed to investigate how progression-free survival (PFS) and OS in older patients with IDH wild-type glioblastoma are impacted by concomitant radio-chemotherapy and MGMT promotor methylation status in real-life settings. This evidence concerns the gene MGMT and glioblastoma.